Beat your own…
Senotherapy is a treatment in which low–molecular-weight drugs are used against aging cells, that is, those cells that are unable to divide.
A group of researchers from the Perelman School of Medicine at the University of Pennsylvania showed in mouse models of hepatocellular carcinoma that senotherapy inhibits the progression of the tumor.
Liver cancer does not respond well to treatment after a certain stage. The incidence is increasing worldwide as the incidence of obesity and viral hepatitis – risk factors for liver cancer – continues to increase.
Researchers have shown that the loss of the enzyme fructose-1,6-bisphosphatase (FBP1) in human liver cells leads to significant tumor progression. The level of FBP1 decreases in stage 1 tumors and further as the disease progresses. The team used RNA sequencing data to show that FBP1 synthesis is always reduced in hepatocellular carcinoma, regardless of other factors such as obesity, alcoholism and hepatitis.
The loss of FBP1 in liver cells activates neighboring stellate liver cells, causing fibrosis (scarring) and subsequent aging of stellate cells, which contribute to tumor growth. The researchers found that aging stellate cells can be selectively destroyed by senolytics (desatenib/quercetin or the drug AVT-263), which leads to inhibition of tumor progression. One of the senolytics (navitoclax) is already undergoing clinical trials for the treatment of malignant neoplasms of the blood.
The group provided evidence that FBP1 is a true metabolic suppressor of liver cell malignancy and that its loss promotes tumor growth due to exposure to healthy cells in the tumor microenvironment. To do this, the researchers eliminated FBP1 in genetically modified mice and found that the disease progresses faster, and the tumor load increases significantly with carcinogen-mediated, dietary and other forms of hepatocellular carcinoma.
Since FBP1 activity also decreases in kidney cancer, the mechanism may be applicable to a number of oncological diseases.
Article F.Li et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome published in the journal Nature Cell Biology.
Aminat Adzhieva, portal "Eternal Youth" http://vechnayamolodost.ru based on EurekAlert materials: New liver cancer research targets non-cancer cells to blunt tumor growth.